17. 多系統萎縮症 Disease details / Clinical trials / Drug dev / DR info

1) inosine 5'-monophosphate
   Yonsei University
      2018   Phase 2   NCT03403309   Korea, Republic of
1-(2-isopropoxyethyl)-2-thioxo-1,2,3,5-tetrahydro-pyrrolo[3,2-D] pyrimidin-4-ONE
   AstraZeneca AB
      2015   Phase 2   EUCTR2014-004902-13-SE   Austria;Finland;France;Italy;Sweden;United Kingdom;United States
      2015   Phase 2   EUCTR2014-004902-13-GB   Finland;Sweden;United Kingdom;United States
      2015   Phase 2   EUCTR2014-004902-13-FI   Austria;Finland;France;Italy;Sweden;United Kingdom;United States
11C-PIB
   Nagoya City Rehabilitation Agency
      2019   -   JPRN-UMIN000036956   Japan
11C-raclopride
   Nagoya City Rehabilitation Agency
      2019   -   JPRN-UMIN000036952   Japan
13N-ammonia
   National Institute of Neurological Disorders and Stroke (NINDS)
      2018   -   NCT03648905   United States
18F-dopa
   National Institute of Neurological Disorders and Stroke (NINDS)
      2018   -   NCT03648905   United States
18F-dopamine
   National Institute of Neurological Disorders and Stroke (NINDS)
      2018   -   NCT03648905   United States
18F-PBR06
   Brigham and Women's Hospital
      2023   -   NCT05486806   United States
AAV2-gdnf gene therapy
   Brain Neurotherapy Bio, Inc.
      2023   Phase 1   NCT04680065   United States
Abdominal compression
   Vanderbilt University Medical Center
      2020   Early Phase 1   NCT04620382   United States
Accelerometer
   Vanderbilt University Medical Center
      2021   -   NCT04782830   United States
Adjuvant without active component
   Affiris AG
      2014   Phase 1   NCT02270489   France
Administration OF carbidopa/levodopa
   Julien Bally
      2025   Phase 1/Phase 2   NCT06831500   Switzerland
Affitope® PD01A + adjuvant
   Affiris AG
      2014   Phase 1   NCT02270489   France
Affitope® PD03A + adjuvant
   Affiris AG
      2014   Phase 1   NCT02270489   France
Aleeto
   Beijing Tiantan Hospital
      2024   Early Phase 1   NCT06765733   China
Allogeneic umbilical cord mesenchymal stem cell and adipose secretome implantation
   Indonesia University
      2020   -   NCT04876326   Indonesia
Allogeneic umbilical cord mesenchymal stem cell implantation
   Indonesia University
      2020   -   NCT04876326   Indonesia
Ampreloxetine
   THERAVANCE BIOPHARMA ANTIBIOTICS, INC.
      2019   Phase 3   EUCTR2018-003289-15-IT   Austria;Bulgaria;Canada;Czechia;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;Poland;Portugal;Russian Federation;Spain;Ukraine;United Kingdom;United States
   Theravance Biopharma
      2023   Phase 3   NCT05696717   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;New Zealand;Poland;Portugal;Spain;Taiwan;United Kingdom;United States
   Theravance Biopharma Ireland Limited
      2020   Phase 3   EUCTR2018-003289-15-DE   Austria;Bulgaria;Canada;Czech Republic;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;Poland;Portugal;Russian Federation;Spain;Ukraine;United Kingdom;United States
      2019   Phase 3   EUCTR2018-003289-15-HU   Austria;Bulgaria;Canada;Czech Republic;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;Poland;Portugal;Russian Federation;Spain;Ukraine;United Kingdom;United States
      2019   Phase 3   EUCTR2018-003289-15-ES   Austria;Canada;Czech Republic;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;Russian Federation;Spain;Ukraine;United Kingdom;United States
Ampreloxetine chydrochloride
   Theravance Biopharma Ireland Limited
      2019   Phase 3   EUCTR2018-003289-15-PL   Argentina;Australia;Austria;Bulgaria;Canada;Chile;Czechia;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;Mexico;New Zealand;Peru;Poland;Portugal;Russian Federation;Spain;Ukraine;United Kingdom;United States
Ampreloxetine hydrochloride
   Theravance Biopharma Ireland Limited
      2020   Phase 3   EUCTR2018-003941-41-PT   Australia;Austria;Bulgaria;Canada;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;New Zealand;Poland;Portugal;Russian Federation;Spain;Ukraine;United Kingdom;United States
      2020   Phase 3   EUCTR2018-003941-41-AT   Argentina;Australia;Austria;Bulgaria;Canada;Chile;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;Mexico;New Zealand;Peru;Poland;Portugal;Russian Federation;Spain;Ukraine;United Kingdom;United States
      2020   Phase 3   EUCTR2018-003289-15-PT   Argentina;Australia;Austria;Bulgaria;Canada;Chile;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;Mexico;New Zealand;Peru;Poland;Portugal;Russian Federation;Spain;Ukraine;United Kingdom;United States
      2019   Phase 3   EUCTR2018-003941-41-PL   Argentina;Australia;Austria;Bulgaria;Canada;Chile;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;Mexico;New Zealand;Peru;Poland;Portugal;Russian Federation;Spain;Ukraine;United Kingdom;United States
      2019   Phase 3   EUCTR2018-003941-41-IT   Australia;Austria;Bulgaria;Canada;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;New Zealand;Poland;Portugal;Russian Federation;Spain;Ukraine;United Kingdom;United States
      2019   Phase 3   EUCTR2018-003941-41-HU   Australia;Austria;Bulgaria;Canada;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;New Zealand;Poland;Portugal;Russian Federation;Spain;Ukraine;United Kingdom;United States
      2019   Phase 3   EUCTR2018-003941-41-GB   Argentina;Australia;Austria;Bulgaria;Canada;Chile;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;Mexico;New Zealand;Peru;Poland;Portugal;Russian Federation;Spain;Ukraine;United Kingdom;United States
      2019   Phase 3   EUCTR2018-003941-41-ES   Australia;Austria;Bulgaria;Canada;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;New Zealand;Poland;Russian Federation;Spain;Ukraine;United Kingdom;United States
      2019   Phase 3   EUCTR2018-003941-41-EE   Argentina;Australia;Austria;Bulgaria;Canada;Chile;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;Mexico;New Zealand;Peru;Poland;Portugal;Russian Federation;Spain;Ukraine;United Kingdom;United States
      2019   Phase 3   EUCTR2018-003941-41-BG   Argentina;Australia;Austria;Bulgaria;Canada;Chile;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;Mexico;New Zealand;Peru;Poland;Portugal;Russian Federation;Spain;Ukraine;United Kingdom;United States
      2019   Phase 3   EUCTR2018-003289-15-GB   Argentina;Australia;Austria;Bulgaria;Canada;Chile;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;Mexico;New Zealand;Peru;Poland;Portugal;Russian Federation;Spain;Ukraine;United Kingdom;United States
      2019   Phase 3   EUCTR2018-003289-15-EE   Australia;Austria;Bulgaria;Canada;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;New Zealand;Poland;Portugal;Russian Federation;Spain;Ukraine;United Kingdom;United States
      2019   Phase 3   EUCTR2018-003289-15-DK   Argentina;Australia;Austria;Bulgaria;Canada;Chile;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;Mexico;New Zealand;Peru;Poland;Portugal;Russian Federation;Spain;Ukraine;United Kingdom;United States
      2019   Phase 3   EUCTR2018-003289-15-BG   Argentina;Australia;Austria;Bulgaria;Canada;Chile;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;Mexico;New Zealand;Peru;Poland;Portugal;Russian Federation;Spain;Ukraine;United Kingdom;United States
      2019   Phase 3   EUCTR2018-003289-15-AT   Argentina;Australia;Austria;Bulgaria;Canada;Chile;Czechia;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;Mexico;New Zealand;Peru;Poland;Portugal;Russian Federation;Spain;Ukraine;United Kingdom;United States
Angiotensin
   Vanderbilt University Medical Center
      2016   Early Phase 1   NCT02591173   United States
ANTI-parkinson medication
   Beth Israel Deaconess Medical Center
      2016   -   NCT02994719   United States
ATH434
   Alterity Therapeutics
      2023   Phase 2   NCT05864365   United States
      2023   Phase 2   NCT05732415   United States
   Alterity Therapeutics Limited
      2022   Phase 2   EUCTR2021-003231-29-IT   Australia;Austria;France;Italy;New Zealand;United Kingdom;United States
ATH434 dose level 1
   Alterity Therapeutics
      2022   Phase 2   NCT05109091   Australia;Austria;France;Italy;New Zealand;United Kingdom;United States
ATH434 dose level 2
   Alterity Therapeutics
      2022   Phase 2   NCT05109091   Australia;Austria;France;Italy;New Zealand;United Kingdom;United States
ATH434 mesylate
   Alterity Therapeutics Limited
      2023   Phase 2   EUCTR2021-003231-29-FR   Australia;Austria;France;Italy;New Zealand;United Kingdom;United States
      2023   Phase 2   EUCTR2021-003231-29-AT   Australia;Austria;France;Italy;New Zealand;United Kingdom;United States
Atomexetine
   NYU Langone Health
      2016   Phase 2   NCT02796209   United States
Autologous adipose mesenchymal stem cell implantation
   Indonesia University
      2020   -   NCT04876326   Indonesia
Autologous mesenchymal stem cells
   Mayo Clinic
      2021   Phase 2   NCT05167721   United States
      2012   Phase 1/Phase 2   NCT02315027   United States
   Yonsei University
      2008   Phase 2   NCT00911365   Korea, Republic of
Automated abdominal binder
   Vanderbilt University Medical Center
      2018   Phase 1/Phase 2   NCT03482297   United States
AV1451 TAU
   Mayo Clinic
      2020   -   NCT04680130   United States
AZD3241
   AstraZeneca
      2015   Phase 2   NCT02388295   Austria;Finland;France;Italy;Sweden;United Kingdom;United States
   AstraZeneca AB
      2010   -   EUCTR2009-018157-23-GB   Austria;Spain;United Kingdom
      2010   -   EUCTR2009-018157-23-ES   Austria;Spain;United Kingdom
      2010   Phase 2   EUCTR2009-018157-23-AT   Austria;Spain;United Kingdom
AZD3241 100MG
   AstraZeneca AB
      2015   Phase 2   EUCTR2014-004902-13-SE   Austria;Finland;France;Italy;Sweden;United Kingdom;United States
      2015   Phase 2   EUCTR2014-004902-13-GB   Finland;Sweden;United Kingdom;United States
      2015   Phase 2   EUCTR2014-004902-13-FI   Austria;Finland;France;Italy;Sweden;United Kingdom;United States
AZD3241 300MG
   AstraZeneca AB
      2015   Phase 2   EUCTR2014-004902-13-SE   Austria;Finland;France;Italy;Sweden;United Kingdom;United States
      2015   Phase 2   EUCTR2014-004902-13-GB   Finland;Sweden;United Kingdom;United States
      2015   Phase 2   EUCTR2014-004902-13-FI   Austria;Finland;France;Italy;Sweden;United Kingdom;United States
Azilect
   Teva Pharmaceutical Industries Ltd
      2010   -   EUCTR2009-014644-11-PT   Austria;France;Germany;Hungary;Italy;Netherlands;Portugal;Spain;United Kingdom
      2010   -   EUCTR2009-014644-11-NL   Austria;France;Germany;Hungary;Italy;Netherlands;Portugal;Spain;United Kingdom
      2010   Phase 2   EUCTR2009-014644-11-GB   Austria;France;Germany;Hungary;Italy;Netherlands;Portugal;Spain;United Kingdom
      2010   -   EUCTR2009-014644-11-AT   Austria;France;Germany;Hungary;Italy;Netherlands;Portugal;Spain;United Kingdom
      2009   -   EUCTR2009-014644-11-IT   Austria;France;Germany;Hungary;Italy;Netherlands;Portugal;Spain;United Kingdom
      2009   -   EUCTR2009-014644-11-HU   Austria;France;Germany;Hungary;Italy;Netherlands;Portugal;Spain;United Kingdom
      2009   Phase 2   EUCTR2009-014644-11-FR   Austria;France;Germany;Hungary;Italy;Netherlands;Portugal;Spain;United Kingdom
      2009   -   EUCTR2009-014644-11-DE   Austria;France;Germany;Hungary;Italy;Netherlands;Portugal;Spain;United Kingdom
Azilect 1 MG comprimidos
   Teva Pharmaceutical Industries Ltd
      2009   Phase 2   EUCTR2009-014644-11-ES   Austria;France;Germany;Hungary;Italy;Netherlands;Portugal;Spain;United Kingdom
BHV-3241
   Biohaven Pharmaceuticals, Inc
      2020   Phase 3   EUCTR2019-001100-38-DE   Austria;China;France;Germany;Italy;United Kingdom;United States
      2019   Phase 3   EUCTR2019-001100-38-GB   Austria;France;Germany;Italy;United Kingdom;United States
      2019   Phase 3   EUCTR2019-001100-38-FR   Austria;France;Germany;Italy;United Kingdom;United States
      2019   Phase 3   EUCTR2019-001100-38-AT   Austria;China;France;Germany;Italy;United Kingdom;United States
   Biohaven Pharmaceuticals, Inc.
      2020   Phase 3   EUCTR2019-001100-38-IT   Austria;China;France;Germany;Italy;United Kingdom;United States
BHV3241, verdiperstat
   Biohaven Pharmaceuticals, Inc.
      2021   -   NCT05086094   United States
Blood sampling
   University Hospital, Bordeaux
      2020   -   NCT04250493   France
Botulinum toxin type A
   Merz Pharmaceuticals GmbH
      2014   Phase 3   EUCTR2012-005539-10-DE   Germany;Poland;United States
BQ123
   Vanderbilt University
      2010   Phase 1   NCT01119417   United States
Bydureon
   University College London (UCL)
      2020   Phase 2   EUCTR2020-000122-26-GB   United Kingdom
   University College, London
      2020   Phase 2   NCT04431713   United Kingdom
C-11 ER176
   Mayo Clinic
      2020   -   NCT04680130   United States
C-11 PIB
   Mayo Clinic
      2020   -   NCT04680130   United States
C11-SY08
   Massachusetts General Hospital
      2024   Early Phase 1   NCT06098612   United States
Captopril
   Vanderbilt University
      2011   Phase 1   NCT01292694   United States
Carbidopa
   National Institute of Neurological Disorders and Stroke (NINDS)
      2007   Phase 1/Phase 2   NCT00547911   United States
Carbidopa 200MG oral dose
   Daniel Claassen
      2020   Phase 1   NCT04246437   United States
Clinical characteristics OF AMS patients
   University Hospital, Bordeaux
      2020   -   NCT04250493   France
Conservative measures FOR orthostatic hypotension
   Royal Brisbane and Women's Hospital
      2005   Phase 1   NCT00103597   Australia
CS10br05
   Corestemchemon, Inc.
      2018   Phase 1   NCT03265444   Korea, Republic of
Deep brain stimulation
   Beth Israel Deaconess Medical Center
      2016   -   NCT02994719   United States
Determination OF objective and subjective pain threshold
   University Hospital, Toulouse
      2011   -   NCT01577992   France
Domperidone
   Royal Brisbane and Women's Hospital
      2005   Phase 1   NCT00103597   Australia
Droxidopa
   Chelsea Therapeutics
      2008   Phase 3   NCT00738062   Australia;Canada;New Zealand;United States
   Loma Linda University
      2021   Phase 2   NCT03446807   United States
   Mount Sinai School of Medicine
      1999   -   NCT00004478   United States
   National Institute of Neurological Disorders and Stroke (NINDS)
      2007   Phase 1/Phase 2   NCT00547911   United States
   Vanderbilt University Medical Center
      2016   Phase 1   NCT02897063   United States
Egcg AS putative neuroprotective agent
   Dr. Johannes Levin
      2014   Phase 3   NCT02008721   Germany
Elecsys (roche) abeta42, ttau and ptau
   Skane University Hospital
      2017   -   NCT03174938   Sweden
Emeramide
   NBMI Science Ltd.
      2019   Phase 2   EUCTR2018-000506-34-SI   Slovenia
Entacapone
   National Institute of Neurological Disorders and Stroke (NINDS)
      2007   Phase 1/Phase 2   NCT00547911   United States
Entacapone 400MG oral dose
   Daniel Claassen
      2020   Phase 1   NCT04246437   United States
Exenatide
   University College London (UCL)
      2020   Phase 2   EUCTR2020-000122-26-GB   United Kingdom
   University College, London
      2020   Phase 2   NCT04431713   United Kingdom
Fipamezole
   Juvantia Pharma Ltd
      2008   Phase 2   NCT00758849   France;Portugal
Fipamezole hydrochloride 30 MG oral disintegrating tablets
   Juvantia Pharma Ltd
      2008   -   EUCTR2007-004890-24-PT   France;Portugal
      2008   -   EUCTR2007-004890-24-FR   France;Portugal
Fipamezole hydrochloride 60 MG oral disintegrating tablets
   Juvantia Pharma Ltd
      2008   -   EUCTR2007-004890-24-PT   France;Portugal
      2008   -   EUCTR2007-004890-24-FR   France;Portugal
Fipamezole hydrochloride 90 MG oral disintegrating tablets
   Juvantia Pharma Ltd
      2008   -   EUCTR2007-004890-24-PT   France;Portugal
      2008   -   EUCTR2007-004890-24-FR   France;Portugal
Fludrocortisone
   Royal Brisbane and Women's Hospital
      2005   Phase 1   NCT00103597   Australia
Flumazenil
   Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
      2013   -   JPRN-UMIN000011111   Japan
Fluoxetine
   University Hospital, Toulouse
      2008   Phase 2   NCT01146548   France
Fluoxétine
   University Hospital, Bordeaux
      2010   -   NCT01136213   France
Flutemetamol F18 injection
   Skane University Hospital
      2017   -   NCT03174938   Sweden
Foralumab nasal
   Brigham and Women's Hospital
      2025   Phase 2   NCT06868628   United States
Green TEA leaf
   Hospital of the Ludwig-Maximilians-University of Munich
      2013   Phase 3   EUCTR2012-000928-18-DE   Germany
H215O PET
   University Hospital, Toulouse
      2002   -   NCT01044992   France
Homsc300
   Cytora Ltd.
      2022   Phase 1   NCT05698017   Israel
HUC-MSC-SEV-001 nasal drops
   Xuanwu Hospital, Beijing
      2024   Phase 1   NCT06607900   China
Human IGG1 monoclonal antibody against alpha-synuclein
   Takeda Development Center Americas, Inc.
      2023   Phase 2   EUCTR2022-000336-28-PT   Austria;Denmark;France;Germany;Italy;Japan;Portugal;Spain;United Kingdom;United States
      2022   Phase 2   EUCTR2022-000336-28-FR   Austria;Denmark;France;Germany;Italy;Japan;Portugal;Spain;United Kingdom;United States
      2022   Phase 2   EUCTR2022-000336-28-ES   Austria;Denmark;France;Germany;Italy;Japan;Portugal;Spain;United Kingdom;United States
      2022   Phase 2   EUCTR2022-000336-28-DK   Austria;Denmark;France;Germany;Italy;Japan;Portugal;Spain;United Kingdom;United States
      2022   Phase 2   EUCTR2022-000336-28-DE   Austria;Denmark;France;Germany;Italy;Japan;Portugal;Spain;United Kingdom;United States
Hydrogen
   Juntendo University School of Medicine, Department of Neurology
      2012   Phase 1   JPRN-UMIN000008959   Japan
Injection
   Merz Pharmaceuticals GmbH
      2014   Phase 3   EUCTR2012-005539-10-DE   Germany;Poland;United States
   Novabio Therapeutics
      2024   Phase 1   NCT06671236   China;United States
   University College London (UCL)
      2020   Phase 2   EUCTR2020-000122-26-GB   United Kingdom
Intranasal insulin
   Peter Novak
      2014   Phase 2   NCT02064166   United States
Intravesical injection OF botulinum A toxin
   University Of Perugia
      2008   Phase 4   NCT00822913   -
ION464
   Ionis Pharmaceuticals, Inc.
      2022   Phase 1   NCT04165486   Austria;France;Germany;Portugal;United Kingdom
JP-1730/F01
   Juvantia Pharma Ltd
      2008   -   EUCTR2007-004890-24-PT   France;Portugal
      2008   -   EUCTR2007-004890-24-FR   France;Portugal
JP-1730/F02
   Juvantia Pharma Ltd
      2008   -   EUCTR2007-004890-24-PT   France;Portugal
      2008   -   EUCTR2007-004890-24-FR   France;Portugal
JP-1730/F03
   Juvantia Pharma Ltd
      2008   -   EUCTR2007-004890-24-PT   France;Portugal
      2008   -   EUCTR2007-004890-24-FR   France;Portugal
KM-819
   Kainos Medicine Inc.
      2023   Phase 2   NCT05695378   Korea, Republic of
L-threo dops
   University Hospital, Toulouse
      2014   Phase 2/Phase 3   NCT02071459   France
Levodopa
   University Hospital, Toulouse
      2002   -   NCT01044992   France
Levodopa test
   University Hospital, Toulouse
      2011   -   NCT01577992   France
Lithium carbonate
   Federico II University
      2009   Phase 2   NCT00997672   Italy
   UNIVERSITA` DEGLI STUDI DI NAPOLI FEDERICO II
      2009   -   EUCTR2009-016377-15-IT   Italy
Litio carbonato
   UNIVERSITA` DEGLI STUDI DI NAPOLI FEDERICO II
      2009   -   EUCTR2009-016377-15-IT   Italy
Losartan
   Vanderbilt University
      2011   Phase 1   NCT01292694   United States
LU AF82422
   H. Lundbeck A/S
      2024   Phase 3   NCT06706622   Australia;Germany;Japan;Korea, Republic of;Spain;United States
      2021   Phase 2   NCT05104476   Japan;United States
Lumipulse (fujirebio) abeta42, ttau and ptau
   Skane University Hospital
      2017   -   NCT03174938   Sweden
Metoprolol tartrate 50 MG
   Vanderbilt University
      2010   -   NCT01044693   United States
Midodrine
   Vanderbilt University Medical Center
      2020   Early Phase 1   NCT04620382   United States
      2018   Phase 1/Phase 2   NCT03482297   United States
      2016   Phase 1   NCT02897063   United States
      2015   Phase 1   NCT02429557   United States
Midodrine or atomoxetine pill
   Vanderbilt University Medical Center
      2021   -   NCT04782830   United States
N1,N3-BIS(2-mercaptoethyl) isophthalamide
   NBMI Science Ltd.
      2019   Phase 2   EUCTR2018-000506-34-SI   Slovenia
Nbmi
   EmeraMed
      2019   Phase 2   NCT04184063   Slovenia
   NBMI Science Ltd.
      2019   Phase 2   EUCTR2018-000506-34-SI   Slovenia
Nebivolol 5 MG
   Vanderbilt University
      2010   -   NCT01044693   United States
Nicotinamide riboside
   Haukeland University Hospital
      2024   Phase 2   NCT06162013   Norway
Nitrogen
   Juntendo University School of Medicine, Department of Neurology
      2012   Phase 1   JPRN-UMIN000008959   Japan
Normal saline
   Yonsei University
      2008   Phase 2   NCT00911365   Korea, Republic of
NP001
   Novabio Therapeutics
      2024   Phase 1   NCT06671236   China;United States
NT 101
   Merz Pharmaceuticals GmbH
      2014   Phase 3   EUCTR2012-005539-10-DE   Germany;Poland;United States
ONO-2808
   Ono Pharmaceutical Co. Ltd
      2023   Phase 2   NCT05923866   Japan;United States
PBT434, 5,7-dichloro-2-((ethylamino)methyl)-8-hydroxy-3-methylquinazolin-4(3H)-ONE mesylate
   Alterity Therapeutics Limited
      2023   Phase 2   EUCTR2021-003231-29-FR   Australia;Austria;France;Italy;New Zealand;United Kingdom;United States
      2023   Phase 2   EUCTR2021-003231-29-AT   Australia;Austria;France;Italy;New Zealand;United Kingdom;United States
PET (positron emission tomography) study
   University Hospital, Bordeaux
      2010   -   NCT01136213   France
Prozac
   CHU Toulouse
      2008   -   EUCTR2007-004922-26-FR   France
Pseudoephedrine
   Vanderbilt University
      2003   Phase 1   NCT00179023   United States
Pseudoephedrine + 480 ML water
   Vanderbilt University
      2014   Early Phase 1   NCT02149901   United States
Pseudoephedrine + 50 ML water
   Vanderbilt University
      2014   Early Phase 1   NCT02149901   United States
Rasagilina mesilato
   Teva Pharmaceutical Industries Ltd
      2009   Phase 2   EUCTR2009-014644-11-ES   Austria;France;Germany;Hungary;Italy;Netherlands;Portugal;Spain;United Kingdom
Rasagiline
   Teva Pharmaceutical Industries Ltd
      2009   -   EUCTR2009-014644-11-IT   Austria;France;Germany;Hungary;Italy;Netherlands;Portugal;Spain;United Kingdom
Rasagiline mesylate
   Teva Pharmaceutical Industries
      2009   Phase 2   NCT00977665   Austria;Canada;France;Germany;Hungary;Israel;Italy;Netherlands;Portugal;Spain;United Kingdom;United States
   Teva Pharmaceutical Industries Ltd
      2010   -   EUCTR2009-014644-11-PT   Austria;France;Germany;Hungary;Italy;Netherlands;Portugal;Spain;United Kingdom
      2010   -   EUCTR2009-014644-11-NL   Austria;France;Germany;Hungary;Italy;Netherlands;Portugal;Spain;United Kingdom
      2010   Phase 2   EUCTR2009-014644-11-GB   Austria;France;Germany;Hungary;Italy;Netherlands;Portugal;Spain;United Kingdom
      2010   -   EUCTR2009-014644-11-AT   Austria;France;Germany;Hungary;Italy;Netherlands;Portugal;Spain;United Kingdom
      2009   -   EUCTR2009-014644-11-HU   Austria;France;Germany;Hungary;Italy;Netherlands;Portugal;Spain;United Kingdom
      2009   Phase 2   EUCTR2009-014644-11-FR   Austria;France;Germany;Hungary;Italy;Netherlands;Portugal;Spain;United Kingdom
      2009   -   EUCTR2009-014644-11-DE   Austria;France;Germany;Hungary;Italy;Netherlands;Portugal;Spain;United Kingdom
Rifampicin
   Phillip Low
      2011   Phase 3   NCT01287221   United States
Riluzole
   King's College London
      2000   Phase 3   NCT00211224   United Kingdom
Safinamide metansolfonato
   ZAMBON SPA
      2019   Phase 2   EUCTR2018-004145-16-IT   Italy;Spain
Safinamide methanesulfonate
   Zambon SpA
      2019   Phase 2   NCT03753763   Italy;Spain
      2019   Phase 2   EUCTR2018-004145-16-ES   Italy;Spain
Saline
   Vanderbilt University
      2010   Phase 1   NCT01119417   United States
   Vanderbilt University Medical Center
      2016   Early Phase 1   NCT02591173   United States
Sham abdominal compression
   Vanderbilt University Medical Center
      2015   Phase 1   NCT02429557   United States
Sham binder
   Vanderbilt University Medical Center
      2018   Phase 1/Phase 2   NCT03482297   United States
Sham compression
   Vanderbilt University Medical Center
      2020   Early Phase 1   NCT04620382   United States
Sildenafil25 MG
   Vanderbilt University
      2010   -   NCT01044693   United States
Sirolimus 2 MG
   NYU Langone Health
      2018   Phase 2   NCT03589976   United States
Sunphenon egcg
   Hospital of the Ludwig-Maximilians-University of Munich
      2013   Phase 3   EUCTR2012-000928-18-DE   Germany
TAK-341
   Takeda
      2022   Phase 2   NCT05526391   Austria;Denmark;France;Germany;Italy;Japan;Portugal;Spain;United Kingdom;United States
   Takeda Development Center Americas, Inc.
      2023   Phase 2   EUCTR2022-000336-28-PT   Austria;Denmark;France;Germany;Italy;Japan;Portugal;Spain;United Kingdom;United States
      2022   Phase 2   EUCTR2022-000336-28-FR   Austria;Denmark;France;Germany;Italy;Japan;Portugal;Spain;United Kingdom;United States
      2022   Phase 2   EUCTR2022-000336-28-ES   Austria;Denmark;France;Germany;Italy;Japan;Portugal;Spain;United Kingdom;United States
      2022   Phase 2   EUCTR2022-000336-28-DK   Austria;Denmark;France;Germany;Italy;Japan;Portugal;Spain;United Kingdom;United States
      2022   Phase 2   EUCTR2022-000336-28-DE   Austria;Denmark;France;Germany;Italy;Japan;Portugal;Spain;United Kingdom;United States
TD-9855
   THERAVANCE BIOPHARMA ANTIBIOTICS, INC.
      2019   Phase 3   EUCTR2018-003289-15-IT   Austria;Bulgaria;Canada;Czechia;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;Poland;Portugal;Russian Federation;Spain;Ukraine;United Kingdom;United States
   Theravance Biopharma
      2016   Phase 2   NCT02705755   United States
   Theravance Biopharma Ireland Limited
      2020   Phase 3   EUCTR2018-003941-41-PT   Australia;Austria;Bulgaria;Canada;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;New Zealand;Poland;Portugal;Russian Federation;Spain;Ukraine;United Kingdom;United States
      2020   Phase 3   EUCTR2018-003941-41-AT   Argentina;Australia;Austria;Bulgaria;Canada;Chile;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;Mexico;New Zealand;Peru;Poland;Portugal;Russian Federation;Spain;Ukraine;United Kingdom;United States
      2020   Phase 3   EUCTR2018-003289-15-PT   Argentina;Australia;Austria;Bulgaria;Canada;Chile;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;Mexico;New Zealand;Peru;Poland;Portugal;Russian Federation;Spain;Ukraine;United Kingdom;United States
      2020   Phase 3   EUCTR2018-003289-15-DE   Austria;Bulgaria;Canada;Czech Republic;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;Poland;Portugal;Russian Federation;Spain;Ukraine;United Kingdom;United States
      2019   Phase 3   EUCTR2018-003941-41-PL   Argentina;Australia;Austria;Bulgaria;Canada;Chile;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;Mexico;New Zealand;Peru;Poland;Portugal;Russian Federation;Spain;Ukraine;United Kingdom;United States
      2019   Phase 3   EUCTR2018-003941-41-IT   Australia;Austria;Bulgaria;Canada;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;New Zealand;Poland;Portugal;Russian Federation;Spain;Ukraine;United Kingdom;United States
      2019   Phase 3   EUCTR2018-003941-41-HU   Australia;Austria;Bulgaria;Canada;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;New Zealand;Poland;Portugal;Russian Federation;Spain;Ukraine;United Kingdom;United States
      2019   Phase 3   EUCTR2018-003941-41-GB   Argentina;Australia;Austria;Bulgaria;Canada;Chile;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;Mexico;New Zealand;Peru;Poland;Portugal;Russian Federation;Spain;Ukraine;United Kingdom;United States
      2019   Phase 3   EUCTR2018-003941-41-ES   Australia;Austria;Bulgaria;Canada;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;New Zealand;Poland;Russian Federation;Spain;Ukraine;United Kingdom;United States
      2019   Phase 3   EUCTR2018-003941-41-EE   Argentina;Australia;Austria;Bulgaria;Canada;Chile;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;Mexico;New Zealand;Peru;Poland;Portugal;Russian Federation;Spain;Ukraine;United Kingdom;United States
      2019   Phase 3   EUCTR2018-003941-41-BG   Argentina;Australia;Austria;Bulgaria;Canada;Chile;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;Mexico;New Zealand;Peru;Poland;Portugal;Russian Federation;Spain;Ukraine;United Kingdom;United States
      2019   Phase 3   EUCTR2018-003289-15-PL   Argentina;Australia;Austria;Bulgaria;Canada;Chile;Czechia;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;Mexico;New Zealand;Peru;Poland;Portugal;Russian Federation;Spain;Ukraine;United Kingdom;United States
      2019   Phase 3   EUCTR2018-003289-15-HU   Austria;Bulgaria;Canada;Czech Republic;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;Poland;Portugal;Russian Federation;Spain;Ukraine;United Kingdom;United States
      2019   Phase 3   EUCTR2018-003289-15-GB   Argentina;Australia;Austria;Bulgaria;Canada;Chile;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;Mexico;New Zealand;Peru;Poland;Portugal;Russian Federation;Spain;Ukraine;United Kingdom;United States
      2019   Phase 3   EUCTR2018-003289-15-ES   Austria;Canada;Czech Republic;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;Russian Federation;Spain;Ukraine;United Kingdom;United States
      2019   Phase 3   EUCTR2018-003289-15-EE   Australia;Austria;Bulgaria;Canada;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;New Zealand;Poland;Portugal;Russian Federation;Spain;Ukraine;United Kingdom;United States
      2019   Phase 3   EUCTR2018-003289-15-DK   Argentina;Australia;Austria;Bulgaria;Canada;Chile;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;Mexico;New Zealand;Peru;Poland;Portugal;Russian Federation;Spain;Ukraine;United Kingdom;United States
      2019   Phase 3   EUCTR2018-003289-15-BG   Argentina;Australia;Austria;Bulgaria;Canada;Chile;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;Mexico;New Zealand;Peru;Poland;Portugal;Russian Federation;Spain;Ukraine;United Kingdom;United States
      2019   Phase 3   EUCTR2018-003289-15-AT   Argentina;Australia;Austria;Bulgaria;Canada;Chile;Czechia;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;Mexico;New Zealand;Peru;Poland;Portugal;Russian Federation;Spain;Ukraine;United Kingdom;United States
TEV-56286
   Teva Branded Pharmaceutical Products R&D, Inc.
      2024   Phase 2   NCT06568237   France;Germany;Israel;Italy;Japan;Spain;United States
THK-5351
   Nagoya University Department of Neurology
      2015   -   JPRN-UMIN000018496   Japan
THK5351
   Nagoya City Rehabilitation Agency
      2019   -   JPRN-UMIN000036956   Japan
Tllsh2910
   National Taiwan University Hospital
      2019   Phase 3   NCT03901638   Taiwan
Tolterodine
   Xuanwu Hospital, Capital Medical University
      2021   -   ChiCTR2100046394   China
Trimethaphan
   Vanderbilt University
      2016   Phase 1   NCT02726711   United States
      2003   Phase 1   NCT00179023   United States
UB-312 injection
   NYU Langone Health
      2023   Phase 1/Phase 2   NCT05634876   United States
Ubiquinol
   Department of Neurology, the University of Tokyo Hospital
      2013   -   JPRN-UMIN000010712   Japan
Verdiperstat
   Biohaven Pharmaceuticals, Inc
      2020   Phase 3   EUCTR2019-001100-38-DE   Austria;China;France;Germany;Italy;United Kingdom;United States
      2019   Phase 3   EUCTR2019-001100-38-GB   Austria;France;Germany;Italy;United Kingdom;United States
      2019   Phase 3   EUCTR2019-001100-38-FR   Austria;France;Germany;Italy;United Kingdom;United States
      2019   Phase 3   EUCTR2019-001100-38-AT   Austria;China;France;Germany;Italy;United Kingdom;United States
   Biohaven Pharmaceuticals, Inc.
      2020   Phase 3   EUCTR2019-001100-38-IT   Austria;China;France;Germany;Italy;United Kingdom;United States
      2019   Phase 3   NCT03952806   Austria;France;Germany;Italy;United Kingdom;United States
Water
   Juntendo University School of Medicine, Department of Neurology
      2012   Phase 1   JPRN-UMIN000008959   Japan
Xadago
   ZAMBON SPA
      2019   Phase 2   EUCTR2018-004145-16-IT   Italy;Spain
   Zambon SpA
      2019   Phase 2   EUCTR2018-004145-16-ES   Italy;Spain
Xeomin
   Merz Pharmaceuticals GmbH
      2014   Phase 3   EUCTR2012-005539-10-DE   Germany;Poland;United States
YA-101
   Yoda Therapeutics Inc.
      2025   Phase 2   NCT06848231   Taiwan;United States
Zoledronic acid 5MG/BAG 100ML INJ
   California Pacific Medical Center Research Institute
      2019   Phase 4   NCT03924414   United States